Natera (NTRA) appoints Thomas Lynch as an independent director, expanding its board to 12 members. Governance and investor implications on 06/05/2026.
Natera (NTRA) files 8‑K with Q4 & FY2025 results and 2026 outlook. Net loss $208.2M, cash $1.076B, operating cash flow $215.3M; Signatera, reimbursement risks.
Natera (NTRA) expands oncology testing with Foresight acquisition announced Dec 4, 2025—strengthens Signatera MRD IP and tumor-informed testing.
Natera (NTRA) reports 34.7% revenue growth in Q3 2025, product revenues $590.2M of $592.2M, and raises 2025 guidance; Signatera drives momentum amid reimbursement and regulatory risks.